SOURCE-LINKED STUDY SUMMARY
Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Full paper summarizedQuality not appraised
- What was studied
- A phase 2 dose-response trial tested survodutide for glycemic control and weight reduction in adults with type 2 diabetes receiving metformin.
- Who / model studied
- The trial randomized 413 adults aged 18–75 years with type 2 diabetes, HbA1c 7.0–10.0%, and BMI 25–50 kg/m².
- Studied dose & schedule
- Subcutaneous survodutide was tested up to 0.3–2.7 mg once weekly or 1.2–1.8 mg twice weekly for 16 weeks, versus placebo and open-label semaglutide up to 1.0 mg weekly.
- What the study found
- HbA1c fell up to 1.71 percentage points and weight up to 8.7%; semaglutide produced 1.47-point and 5.3% reductions. Adverse events occurred in 77.8% with survodutide, mainly gastrointestinal.
- Limitations & context
- Semaglutide was open-label and served as a reference, not a powered superiority comparator. Rapid escalation, short treatment, and 15.9% adverse-event discontinuation with survodutide limit interpretation.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1007/s00125-023-06053-9